Posted inGastroenterology news Oncology
Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard
A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatment strategies based on pathological response.